Tofacitinib, the first JAK inhibitor to be studied and approved (by FDA) in humans for treating RA and other autoimmune diseases, can efficiently inhibit JAK1 and JAK3 and, to a lower extent, JAK2 [8,9]. This evidence concerns the gene JAK2 and rheumatoid arthritis.